跳至主要内容
临床试验/jRCT1040230010
jRCT1040230010招募中不适用

Development of proactive antimicrobial strategy using novel rapid test complex for microorganisms during pancreatoduodenectomy (DOREMI trial)

University of Toyama0 个研究点目标入组 150 人开始时间: 2022年12月1日最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
150
主要终点
-

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomized Controlled Trial
干预模型
Single Assignment
主要目的
Treatment Purpose
盲法
Open(masking Not Used)

入排标准

年龄范围
20age old over 至 No limit(—)
性别
All

入选标准

  • Patients are scheduled to undergo pancreaticoduodenectomy.
  • Patients must be at least 20 years of age at the time of enrollment.
  • ECOG PS status 0, 1, or 2
  • The patient's consent to participate in this study was obtained.

排除标准

  • History of serious drug hypersensitivity or drug allergy.
  • Patients have obvious preoperative infection or inflammation (e.g., fever over 38.0 digree).
  • Patient has a serious underlying disease (cardiac, pulmonary, metabolic, renal, cirrhosis, bowel obstruction, etc.) and is considered by the surgeon to be at high risk (more than 5%) of surgery-related mortality.
  • Patients have dementia, psychosis, or psychiatric symptoms.
  • Other conditions that make them unsuitable for the study as determined by the study investigator(s).

结局指标

主要结局

-

RMiX-PAT Treatment compliance rate

次要结局

未报告次要终点

研究者

相似试验